Breast CancerBrCaNCT06830590
Study of Molecular Characterisation of Early Operable Primary Breast Cancer in Pakistani Population
An observational study of Breast Cancer and Molecular Pathway Deregulation, run by Liaquat University of Medical & Health Sciences at 1 site in Pakistan.
Trial summary
This study is looking at the biological characteristics of early operable primary breast cancer in Pakistani Population by using IHC Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Breast Cancer, Molecular Pathway Deregulation, Treatment
- What is being tested?
- Molecular characterisation
- Type of treatment
- Surgery or procedure
- How many people
- 300 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Feb 2016to 31 Dec 2025
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Study population: The population are women with early operable primary breast cancer underwent surgery without any prior treatment.
Who may be able to join
- Women with confirmed diagnosis of breast cancer without history of taking neoadjuvant therapy Good quality tumour samples available for IHC
Who cannot join
- patients received pre-operative chemotherapy or radiotherapy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site, 1 recruiting
- Recruiting
Binafsha M Syed
Jamshoro
Binafsha M Syed, 03332749201, drbinafsha@hotmail.com
drbinafsha@hotmail.com
About this study
This study is looking at the biological characteristics of early operable primary breast cancer in Pakistani Population by using IHC
- Conditions
- Breast Cancer, Molecular Pathway Deregulation, Treatment
- Being tested
- Molecular characterisation
- Keywords
- Breast cancer, Molecular characterisation
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Molecular characterisationProcedure or surgery
All patients treated by surgery were included without any neoadjuvant therapy
| Study group | Role | What they receive |
|---|---|---|
| Early operable primary breast cancer | 1. women
2. any age group
3. confirmed diagnosis of breast cancer Receives: Procedure: Molecular characterisation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Breast cancer specific survival in correlation with molecular pattern
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2025
- Study start1 Feb 2016
- Primary completion30 Dec 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 300 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Liaquat University of Medical & Health Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof. Binafsha Manzoor Syed, Liaquat University of Medical & Health Sciences
- Investigators
- Binafsha Manzoor M Syed, MBBS, PhD, Principal investigator, Liaquat University of Medical & Health Sciences, Jamshoro
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06830590
- Sponsor's protocol ID
- BreastCa001
- Acronym
- BrCa
- Status last verified
- Aug 2025
- First submitted
- 11 Feb 2025
- Last updated
- 13 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: data will be shared in the form of overall results with pattern of biomarkers. Individual participants data will not be shared
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Molecular Characterisation of Early Operable Primary Breast Cancer in Pakistani Population
- ClinicalTrials.gov ID
- NCT06830590
- Acronym / sponsor ID
- BrCa / BreastCa001
- Conditions
- Breast Cancer, Molecular Pathway Deregulation, Treatment
- Keywords
- Breast cancer, Molecular characterisation
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Liaquat University of Medical & Health SciencesUniversity, hospital or other
- Study start
- 1 Feb 2016 (actual)
- Primary completion
- 30 Dec 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 17 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is looking at the biological characteristics of early operable primary breast cancer in Pakistani Population by using IHC
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 10 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Early operable primary breast cancer | – | Procedure: Molecular characterisation1. women 2. any age group 3. confirmed diagnosis of breast cancer |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The population are women with early operable primary breast cancer underwent surgery without any prior treatment.
Key inclusion criteria (1 listed)
- Women with confirmed diagnosis of breast cancer without history of taking neoadjuvant therapy Good quality tumour samples available for IHC
Key exclusion criteria (1 listed)
- patients received pre-operative chemotherapy or radiotherapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Molecular characterisationAll patients treated by surgery were included without any neoadjuvant therapy | Procedure or surgery | Early operable primary breast cancer |
Primary outcome
Breast cancer specific survival in correlation with molecular pattern
Time frame: 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2025.
- Individual participant dataSharing planned: No. data will be shared in the form of overall results with pattern of biomarkers. Individual participants data will not be shared
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Binafsha Manzoor M Syed, MBBS, PhD principal investigator
Liaquat University of Medical & Health Sciences, Jamshoro
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer and Molecular Pathway Deregulation, run by Liaquat University of Medical & Health Sciences at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Binafsha Manzoor M Syed, MBBS, PhD (+923332749201, Binafsha.syed@lumhs.edu.pk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Breast cancer specific survival in correlation with molecular pattern (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2025.